158 related articles for article (PubMed ID: 33314138)
1. Prostatic Pharmacokinetic/Pharmacodynamic Evaluation of Ampicillin-Sulbactam for Bacterial Prostatitis and Preoperative Prophylaxis.
Onita T; Ikawa K; Nakamura K; Nishikawa G; Kobayashi I; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
J Clin Pharmacol; 2021 Jun; 61(6):820-831. PubMed ID: 33314138
[TBL] [Abstract][Full Text] [Related]
2. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of flomoxef in prostate tissue and dosing considerations for prostatitis based on site-specific pharmacodynamic target attainment.
Nakamura K; Ikawa K; Nishikawa G; Kobayashi I; Tobiume M; Sugie M; Muramatsu H; Morinaga S; Kajikawa K; Watanabe M; Kanao K; Onita T; Morikawa N
J Infect Chemother; 2020 Feb; 26(2):236-241. PubMed ID: 31822449
[TBL] [Abstract][Full Text] [Related]
4. Determination of doripenem penetration into human prostate tissue and assessment of dosing regimens for prostatitis based on site-specific pharmacokinetic-pharmacodynamic evaluation.
Nakamura K; Ikawa K; Yamada Y; Arakawa M; Zennami K; Nishikawa G; Ikeda K; Morikawa N; Honda N
J Chemother; 2012 Feb; 24(1):32-7. PubMed ID: 22546722
[TBL] [Abstract][Full Text] [Related]
5. Penetration of a single infusion of ampicillin and sulbactam into prostatic tissue during transurethral prostatectomy.
Klotz T; Braun M; Bin Saleh A; Orlovski M; Engelmann U
Int Urol Nephrol; 1999; 31(2):203-9. PubMed ID: 10481965
[TBL] [Abstract][Full Text] [Related]
6. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.
Nishikawa G; Ikawa K; Nakamura K; Yamada Y; Zennami K; Mitsui K; Narushima M; Ikeda K; Morikawa N; Sumitomo M
Int J Antimicrob Agents; 2013 Mar; 41(3):267-71. PubMed ID: 23313536
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacokinetics and pharmacodynamic target attainment of pazufloxacin in prostate tissue: Dosing considerations for prostatitis.
Nakamura K; Ikawa K; Nishikawa G; Kobayashi I; Narushima M; Muramatsu H; Morinaga S; Kajikawa K; Kato Y; Watanabe M; Zennami K; Kanao K; Morikawa N; Sumitomo M
J Infect Chemother; 2017 Dec; 23(12):809-813. PubMed ID: 28923301
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Soto E; Shoji S; Muto C; Tomono Y; Marshall S
Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
[TBL] [Abstract][Full Text] [Related]
9. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
10. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
Majcher-Peszynska J; Loebermann M; Klammt S; Frimmel S; Mundkowski RG; Welte T; Reisinger EC; Drewelow B;
Infection; 2014 Feb; 42(1):79-87. PubMed ID: 23904004
[TBL] [Abstract][Full Text] [Related]
11. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
Suzuki K; Horiba M
Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830214
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery.
Wildfeuer A; Mallwitz J; Gotthardt H; Hille E; Gruber H; Dahmen G; Pfaff G; Göbel C
Infection; 1997; 25(4):258-62. PubMed ID: 9266270
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery.
Yokoyama Y; Matsumoto K; Yamamoto H; Iguro Y; Imoto Y; Ikawa K; Morikawa N; Ishida S; Okano Y; Watanabe E; Shimodozono Y; Yamada K; Takeda Y
J Infect Chemother; 2012 Dec; 18(6):878-82. PubMed ID: 22644082
[TBL] [Abstract][Full Text] [Related]
15. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.
Alexov M; Lister PD; Sanders CC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2468-77. PubMed ID: 8913448
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Pediatr Infect Dis J; 2022 May; 41(5):411-416. PubMed ID: 35195566
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Yamamoto H; Imoto Y; Morikawa N; Takeda Y
Biol Pharm Bull; 2015; 38(11):1817-21. PubMed ID: 26521833
[TBL] [Abstract][Full Text] [Related]
19. Model-Informed Clinical Practice - Determining an Appropriate Ampicillin-Sulbactam Redosing Regimen in Surgical Patients by Utilizing Population Pharmacokinetics and Target Attainment Analysis.
Reeder JA; O'Sullivan CT; Xu M; Wu N; Ince D; Rogers WK; An G
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0124822. PubMed ID: 36920230
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
